Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03681938 | Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission? | unknown | — | 183 | Institut Paoli-CalmettesOTHER | 1 | Sep 24, 2018 | clinicaltrials |
| NCT03674710 | A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques(EUS-FNA) | unknown | N/A | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 17, 2018 |
| clinicaltrials |
| NCT03558412 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | unknown | Phase 4 | 40 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03579082 | A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 60 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03671460 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 | 18 | Tianjin Mycure Medical Technology Co., LtdINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03664661 | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02800447 | Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol | unknown | N/A | 92 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Sep 4, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT02187731 | Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma(FULIMA) | unknown | — | 70 | Odense University HospitalOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT03454945 | Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides | unknown | Phase 3 | 30 | Cairo UniversityOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT02572492 | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support(CARFI) | unknown | Phase 2 | 200 | Henrik GregersenOTHER | 5 | Aug 17, 2018 | clinicaltrials |
| NCT03631862 | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Zhengzhou UniversityOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03623087 | SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | unknown | Phase 3 | 68 | The University of Hong KongOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03613428 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | unknown | Phase 1 / Phase 2 | 12 | Sichuan UniversityOTHER | 0 | Aug 3, 2018 | clinicaltrials |
| NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients(DLBCL) | unknown | Phase 2 | 39 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02888977 | Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL(EWALL_OBS) | unknown | — | 100 | Versailles HospitalOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03605056 | Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | unknown | Phase 2 | 25 | Peng LiuOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03283111 | Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | unknown | N/A | 150 | Peking UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03598959 | Tofacitinib Combined With Chidamide in R/R ENKTCL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03602131 | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | unknown | Phase 2 | 30 | Sichuan UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT01429610 | Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia(RADICAL) | unknown | Phase 2 | 78 | Asan Medical CenterOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03151876 | Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 93 | Sichuan UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03528421 | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | unknown | Phase 1 | 30 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT03586401 | Creating a Decision Support System for the Corporate Management of Physical Therapy | unknown | — | 1,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT03578718 | Evaluation of the Interest of a Specialist in Dermatology for Dermatopediatric Consultations(HLSkinPed) | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 0 | Jul 6, 2018 | clinicaltrials |
| NCT03564977 | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation | unknown | N/A | 20 | Qingdao Central HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03574168 | CD19-CAR-T Cells in Patients With R/R B-ALL | unknown | Phase 1 | 40 | Bioceltech Therapeutics, Ltd.INDUSTRY | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03556748 | WB-EMS and Nutrition in Patients With Hematological Malignancies | unknown | N/A | 40 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unknown | Phase 3 | 100 | Southwest Hospital, ChinaOTHER | 0 | Jun 12, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT03071822 | Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas | unknown | Phase 4 | 50 | The University of Hong KongOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT03143036 | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 4 | Jun 7, 2018 | clinicaltrials |
| NCT03540303 | Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | May 30, 2018 | clinicaltrials |
| NCT03540849 | BV After Allogeneic Hematopoietic Stem Cell Transplantation(BV-ALLO) | unknown | Phase 2 | 58 | University Hospital, CaenOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02158702 | Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03515915 | Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment | unknown | — | 30 | University Hospital, MontpellierOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02451774 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction(PTX-II) | unknown | Phase 2 / Phase 3 | 44 | Ramón Óscar González-Ramella, Ph.DOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT03513601 | Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT02371161 | Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy | unknown | Phase 2 | 135 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01906671 | Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid | unknown | Phase 4 | 16 | Kjeld SchmiegelowOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT02732236 | Marginal Zone Lymphoma Cohort in Korea | unknown | — | 500 | Dong-A University HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT03495492 | Chronic Lymphocytic Leukemia Responds to Dermal Chelation | unknown | N/A | 50 | Optimum Health, Natural Healthcare CenterOTHER | 0 | Apr 12, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Sep 24, 2018source: clinicaltrials